These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35924681)

  • 1. Clinical evaluation of urine laminin-γ2 monomer as a potent biomarker for non-muscle invasive bladder cancer.
    Karashima T; Umemoto S; Kishida T; Osaka K; Nakagawa M; Yoshida E; Yoshimura T; Sakaguchi M; Nishimoto H; Tai M; Inoue K; Seiki M; Koshikawa N; Shuin T
    Cancer Med; 2023 Feb; 12(3):2453-2462. PubMed ID: 35924681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
    Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
    Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma.
    Kamada M; Koshikawa N; Minegishi T; Kawada C; Karashima T; Shuin T; Seiki M
    Cancer Sci; 2015 Dec; 106(12):1730-7. PubMed ID: 26450632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer.
    Nakagawa M; Karashima T; Kamada M; Yoshida E; Yoshimura T; Nojima M; Inoue K; Shuin T; Seiki M; Koshikawa N
    Biomark Res; 2017; 5():29. PubMed ID: 29046806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte transformation is induced by laminin γ2 monomer.
    Funahashi N; Okada H; Kaneko R; Nio K; Yamashita T; Koshikawa N
    Cancer Sci; 2024 Jul; ():. PubMed ID: 38951133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
    Kurokawa S; Morita T; Muraishi O; Tokue A
    Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.